Cargando…

Prognostic impact of implantable cardioverter defibrillators and associated adverse events in patients with continuous flow left ventricular assist devices

OBJECTIVES: Implantation of implantable cardioverter defibrillators (ICD) reduces the risk of all-cause mortality in symptomatic heart failure (HF) patients with severe left ventricular (LV) dysfunction. Nevertheless, the prognostic impact of ICD therapy in continuous flow left ventricular assist de...

Descripción completa

Detalles Bibliográficos
Autores principales: Pausch, Jonas, Mersmann, Julian, Bhadra, Oliver D., Barten, Markus J., Tönnis, Tobias, Yildirim, Yalin, Pecha, Simon, Reichenspurner, Hermann, Bernhardt, Alexander M.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10272823/
https://www.ncbi.nlm.nih.gov/pubmed/37332585
http://dx.doi.org/10.3389/fcvm.2023.1158248
_version_ 1785059583442550784
author Pausch, Jonas
Mersmann, Julian
Bhadra, Oliver D.
Barten, Markus J.
Tönnis, Tobias
Yildirim, Yalin
Pecha, Simon
Reichenspurner, Hermann
Bernhardt, Alexander M.
author_facet Pausch, Jonas
Mersmann, Julian
Bhadra, Oliver D.
Barten, Markus J.
Tönnis, Tobias
Yildirim, Yalin
Pecha, Simon
Reichenspurner, Hermann
Bernhardt, Alexander M.
author_sort Pausch, Jonas
collection PubMed
description OBJECTIVES: Implantation of implantable cardioverter defibrillators (ICD) reduces the risk of all-cause mortality in symptomatic heart failure (HF) patients with severe left ventricular (LV) dysfunction. Nevertheless, the prognostic impact of ICD therapy in continuous flow left ventricular assist device (LVAD) recipients remains controversial. METHODS: 162 consecutive HF patients, who underwent LVAD implantation at our institution between 2010 and 2019, were categorized according to the presence (n = 94, ICD-group) or absence (n = 68, Control-group) of ICDs. Apart from clinical baseline and follow-up parameters, adverse events (AEs) related to ICD therapy and overall survival rates were retrospectively analyzed. RESULTS: Out of 162 consecutive LVAD recipients 79 patients (48.8%) were preoperatively categorized as Interagency Registry for Mechanically Assisted Circulatory Support (INTERMACS) profile ≤2. The prevalence of severe HF symptoms and preoperative use of short-term circulatory support devices (54.4% vs. 13.8%, p < 0.001) was higher within the Control-group, although baseline severity of LV and RV dysfunction was similar. Apart from an increased prevalence of perioperative right heart failure (RHF) within the Control-group (45.6% vs. 17.0%; p < 0.001), procedural characteristics and perioperative outcome were similar. Overall-survival during a median follow-up of 14 (3.0–36.5) months was similar within both groups (p = 0.46). During the first 2 years after LVAD implantation 53 ICD-related AEs occurred within the ICD-group. Thereof, lead-dysfunction occurred in 19 patients and unplanned ICD-reintervention in 11 patients. Furthermore, in 18 patients appropriate shocks without loss of consciousness occurred, whereas inappropriate shocks occurred in 5 patients. CONCLUSION: ICD therapy in LVAD recipients was not associated with a survival benefit or reduced morbidity after LVAD implantation. Conservative ICD-programming seems to be justified to avoid ICD-related complications and „awake shocks” after LVAD implantation.
format Online
Article
Text
id pubmed-10272823
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-102728232023-06-17 Prognostic impact of implantable cardioverter defibrillators and associated adverse events in patients with continuous flow left ventricular assist devices Pausch, Jonas Mersmann, Julian Bhadra, Oliver D. Barten, Markus J. Tönnis, Tobias Yildirim, Yalin Pecha, Simon Reichenspurner, Hermann Bernhardt, Alexander M. Front Cardiovasc Med Cardiovascular Medicine OBJECTIVES: Implantation of implantable cardioverter defibrillators (ICD) reduces the risk of all-cause mortality in symptomatic heart failure (HF) patients with severe left ventricular (LV) dysfunction. Nevertheless, the prognostic impact of ICD therapy in continuous flow left ventricular assist device (LVAD) recipients remains controversial. METHODS: 162 consecutive HF patients, who underwent LVAD implantation at our institution between 2010 and 2019, were categorized according to the presence (n = 94, ICD-group) or absence (n = 68, Control-group) of ICDs. Apart from clinical baseline and follow-up parameters, adverse events (AEs) related to ICD therapy and overall survival rates were retrospectively analyzed. RESULTS: Out of 162 consecutive LVAD recipients 79 patients (48.8%) were preoperatively categorized as Interagency Registry for Mechanically Assisted Circulatory Support (INTERMACS) profile ≤2. The prevalence of severe HF symptoms and preoperative use of short-term circulatory support devices (54.4% vs. 13.8%, p < 0.001) was higher within the Control-group, although baseline severity of LV and RV dysfunction was similar. Apart from an increased prevalence of perioperative right heart failure (RHF) within the Control-group (45.6% vs. 17.0%; p < 0.001), procedural characteristics and perioperative outcome were similar. Overall-survival during a median follow-up of 14 (3.0–36.5) months was similar within both groups (p = 0.46). During the first 2 years after LVAD implantation 53 ICD-related AEs occurred within the ICD-group. Thereof, lead-dysfunction occurred in 19 patients and unplanned ICD-reintervention in 11 patients. Furthermore, in 18 patients appropriate shocks without loss of consciousness occurred, whereas inappropriate shocks occurred in 5 patients. CONCLUSION: ICD therapy in LVAD recipients was not associated with a survival benefit or reduced morbidity after LVAD implantation. Conservative ICD-programming seems to be justified to avoid ICD-related complications and „awake shocks” after LVAD implantation. Frontiers Media S.A. 2023-06-02 /pmc/articles/PMC10272823/ /pubmed/37332585 http://dx.doi.org/10.3389/fcvm.2023.1158248 Text en © 2023 Pausch, Mersmann, Bhadra, Barten, Tönnis, Yildirim, Pecha, Reichenspurner and Bernhardt. https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY) (https://creativecommons.org/licenses/by/4.0/) . The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Cardiovascular Medicine
Pausch, Jonas
Mersmann, Julian
Bhadra, Oliver D.
Barten, Markus J.
Tönnis, Tobias
Yildirim, Yalin
Pecha, Simon
Reichenspurner, Hermann
Bernhardt, Alexander M.
Prognostic impact of implantable cardioverter defibrillators and associated adverse events in patients with continuous flow left ventricular assist devices
title Prognostic impact of implantable cardioverter defibrillators and associated adverse events in patients with continuous flow left ventricular assist devices
title_full Prognostic impact of implantable cardioverter defibrillators and associated adverse events in patients with continuous flow left ventricular assist devices
title_fullStr Prognostic impact of implantable cardioverter defibrillators and associated adverse events in patients with continuous flow left ventricular assist devices
title_full_unstemmed Prognostic impact of implantable cardioverter defibrillators and associated adverse events in patients with continuous flow left ventricular assist devices
title_short Prognostic impact of implantable cardioverter defibrillators and associated adverse events in patients with continuous flow left ventricular assist devices
title_sort prognostic impact of implantable cardioverter defibrillators and associated adverse events in patients with continuous flow left ventricular assist devices
topic Cardiovascular Medicine
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10272823/
https://www.ncbi.nlm.nih.gov/pubmed/37332585
http://dx.doi.org/10.3389/fcvm.2023.1158248
work_keys_str_mv AT pauschjonas prognosticimpactofimplantablecardioverterdefibrillatorsandassociatedadverseeventsinpatientswithcontinuousflowleftventricularassistdevices
AT mersmannjulian prognosticimpactofimplantablecardioverterdefibrillatorsandassociatedadverseeventsinpatientswithcontinuousflowleftventricularassistdevices
AT bhadraoliverd prognosticimpactofimplantablecardioverterdefibrillatorsandassociatedadverseeventsinpatientswithcontinuousflowleftventricularassistdevices
AT bartenmarkusj prognosticimpactofimplantablecardioverterdefibrillatorsandassociatedadverseeventsinpatientswithcontinuousflowleftventricularassistdevices
AT tonnistobias prognosticimpactofimplantablecardioverterdefibrillatorsandassociatedadverseeventsinpatientswithcontinuousflowleftventricularassistdevices
AT yildirimyalin prognosticimpactofimplantablecardioverterdefibrillatorsandassociatedadverseeventsinpatientswithcontinuousflowleftventricularassistdevices
AT pechasimon prognosticimpactofimplantablecardioverterdefibrillatorsandassociatedadverseeventsinpatientswithcontinuousflowleftventricularassistdevices
AT reichenspurnerhermann prognosticimpactofimplantablecardioverterdefibrillatorsandassociatedadverseeventsinpatientswithcontinuousflowleftventricularassistdevices
AT bernhardtalexanderm prognosticimpactofimplantablecardioverterdefibrillatorsandassociatedadverseeventsinpatientswithcontinuousflowleftventricularassistdevices